Eledon Pharmaceuticals, Inc.

NasdaqCM:ELDN Stock Report

Market Cap: US$305.3m

Eledon Pharmaceuticals Management

Management criteria checks 3/4

Eledon Pharmaceuticals' CEO is DA Gros, appointed in Sep 2020, has a tenure of 5.83 years. total yearly compensation is $3.22M, comprised of 19.1% salary and 80.9% bonuses, including company stock and options. directly owns 0.012% of the company’s shares, worth $35.54K. The average tenure of the management team and the board of directors is 5.3 years and 5.7 years respectively.

Key information

DA Gros

Chief executive officer

US$3.2m

Total compensation

CEO salary percentage19.07%
CEO tenure5.8yrs
CEO ownership0.01%
Management average tenure5.3yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

Analysis Article • Mar 24

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • May 07

Companies Like Eledon Pharmaceuticals (NASDAQ:ELDN) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Jan 28

Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business

Summary Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell transplantation. Early trials indicate Tegoprubart's safety and efficacy, with no major side effects and better kidney function compared to current standards like tacrolimus. Eledon has a market cap of $264mn, a cash balance of $78mn, and a cash runway of 7-8 quarters, but remains a high-risk investment. While it's too early for large investments, a small pilot position could be warranted based on promising early data and unmet medical needs. Read the full article on Seeking Alpha
Seeking Alpha • Oct 29

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Summary Positive phase 1b biomarker and eGFR data achieved from phase 1b study using tegoprubart for prevention of organ rejection in kidney transplant patients. Top-line data from the phase 2 BESTOW study, using tegoprubart for prevention of organ rejection in kidney transplant patients, expected in Q4 of 2025. The organ transplant immunosuppressant drugs market is expected to reach $6.4 billion by 2030. Positive data obtained from investigator-sponsored phase 1/2 trial, using tegoprubart for islet cell transplantation in patients with Type 1 Diabetes. Read the full article on Seeking Alpha
Analysis Article • Mar 22

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 05

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Aug 10

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Apr 27

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 05

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 06

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

The shares of clinical-stage biotech Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) gained 10% in post-market trading Friday after the company announced that the FDA cleared its Investigational New Drug (IND) application for kidney disease therapy tegoprubart. Phase 2a trial for the candidate is currently underway globally, targeting patients with IgA Nephropathy, which can lead to End-Stage Renal Disease, dialysis, renal transplant, and death with a progressive impact on kidney function. With the IND clearance for tegoprubart in IgA, the company plans to open U.S. trial sites for the open-label study, which will enroll up to 21 patients worldwide in each of the two dose cohorts. Following regulatory clearance in 10 countries to study tegoprubart in IgA, ELDN plans to expand the trial to two more countries, including China. Early August, ELDN announced that the FDA greenlighted a mid-stage trial for tegoprubart as a treatment to prevent organ rejection in patients who underwent a kidney transplant.
Analysis Article • Aug 31

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 01

Eledon gets FDA nod to start trial of organ rejection preventing therapy

Eledon Pharmaceuticals (NASDAQ:ELDN) said the U.S. Food and Drug Administration (FDA) cleared its investigational new drug application seeking to start a phase 2 trial of tegoprubart for preventing organ rejection in patients receiving a kidney transplant. The study will enroll ~120 people (60 in each group) undergoing kidney transplant  who will receive tegoprubart or the active comparator tacrolimus, sold as Prograf by Astellas Pharma (OTCPK:ALPMY) (OTCPK:ALPMF), as part of an immunosuppressive regimen including corticosteroids and mycophenolate mofetil or mycophenolate sodium. The trial's main goal is to assess superiority of graft function by comparing the mean estimated glomerular filtration rate (eGFR) at  12 months post-transplant in one group against the other. Secondary goals include safety, incidence of new onset diabetes, and participant and graft survival. "We believe strongly in tegoprubart’s potential to supplant CNIs in the immunosuppressive regimen of kidney transplant patients, potentially leading to reduced side effects such as diabetes and hypertension, better kidney allograft function, and a resulting longer functional life of transplanted kidneys," said Eledon CEO David-Alexandre Gros.
Seeking Alpha • Jul 18

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Eledon Pharmaceuticals (NASDAQ:ELDN) said the first patient was dosed in a phase 1b trial of tegoprubart in patients undergoing kidney transplantation. In the study, which received clearance in Canada and the U. K., is enrolling up to 12 patients who will undergo kidney transplantation and will receive tegoprubart in combination with rabbit anti-thymocyte globulin (rATG) induction, and mycophenolate mofetil and an oral steroid taper as maintenance therapy. "We believe tegoprubart has the potential to transform the clinical management of kidney transplantation by preventing graft rejection, mitigating the multiple toxicities associated with CNIs, and ultimately improving long term outcomes," said Eledon CEO David-Alexandre Gros. In June, the U.S. Food and Drug Administration granted orphan drug designation to tegoprubart for preventing allograft rejection in pancreatic islet cell transplantation.
Analysis Article • Apr 14

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 21

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

A look at the shareholders of Eledon Pharmaceuticals, Inc. ( NASDAQ:ELDN ) can tell us which group is most powerful...
Analysis Article • Dec 30

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO Compensation Analysis

How has DA Gros's remuneration changed compared to Eledon Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$78m

Dec 31 2025US$3mUS$613k

-US$46m

Sep 30 2025n/an/a

-US$83m

Jun 30 2025n/an/a

US$15m

Mar 31 2025n/an/a

-US$19m

Dec 31 2024US$6mUS$582k

-US$36m

Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$128m

Mar 31 2024n/an/a

-US$129m

Dec 31 2023US$3mUS$559k

-US$117m

Sep 30 2023n/an/a

-US$145m

Jun 30 2023n/an/a

-US$145m

Mar 31 2023n/an/a

-US$89m

Dec 31 2022US$1mUS$533k

-US$88m

Sep 30 2022n/an/a

-US$38m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$36m

Dec 31 2021US$748kUS$504k

-US$35m

Sep 30 2021n/an/a

-US$32m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$7mUS$150k

-US$23m

Compensation vs Market: DA's total compensation ($USD3.22M) is above average for companies of similar size in the US market ($USD2.46M).

Compensation vs Earnings: DA's compensation has been consistent with company performance over the past year.

CEO

DA Gros (54 yo)

5.8yrs
Tenure
US$3,216,148
Compensation

Dr. David-Alexandre C. Gros, also known as DA, M.D., Ph D., serves as Chief Executive Officer and Non-Independent Director at Eledon Pharmaceuticals, Inc. since September 09, 2020. Dr. Gros served as an ad...

Leadership Team

NamePositionTenureCompensationOwnership
David-Alexandre Gros
CEO & Non Independent Director5.8yrsUS$3.22m0.012%
$ 35.5k
Steven Perrin
President5.8yrsUS$1.70m0.0013%
$ 3.9k
Paul Little
Chief Financial Officer5.3yrsUS$1.59m0.013%
$ 39.5k
John Herberger
Vice President of Technical Operationsno datano datano data
Bryan Smith
General Counsel5.3yrsUS$1.68mno data
David Hovland
Chief Regulatory Officer5.3yrsno datano data
Marina Escudero
VP & Head of Clinical Operations2.5yrsno datano data
5.3yrs
Average Tenure
57yo
Average Age

Experienced Management: ELDN's management team is seasoned and experienced (5.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David-Alexandre Gros
CEO & Non Independent Director5.8yrsUS$3.22m0.012%
$ 35.5k
Steven Perrin
President5.8yrsUS$1.70m0.0013%
$ 3.9k
Keith Katkin
Independent Chairman of the Board9.2yrsUS$487.71k0.012%
$ 36.5k
John McBride
Independent Director9.2yrsUS$192.25k0.0044%
$ 13.6k
James Robinson
Independent Director2.8yrsUS$189.41k0.0044%
$ 13.6k
Jan Hillson
Independent Director5yrsUS$175.21k0.0044%
$ 13.6k
June H. Lee
Independent Director5.6yrsUS$192.25k0.0044%
$ 13.6k
Allan Kirk
Independent Director2.8yrsUS$183.14k0.0044%
$ 13.6k
5.7yrs
Average Tenure
60yo
Average Age

Experienced Board: ELDN's board of directors are considered experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/05 03:34
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eledon Pharmaceuticals, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Alethia YoungCantor Fitzgerald & Co.
Pete StavropoulosCantor Fitzgerald & Co.